Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Study Evaluating the Body Weight Progress During the Treatment With Insulin Detemir (Levemir) in Type 2 Patients, Previously Treated With Other Basal Insulins.

Next Previous
Search
Trial Profile

Observational Study Evaluating the Body Weight Progress During the Treatment With Insulin Detemir (Levemir) in Type 2 Patients, Previously Treated With Other Basal Insulins.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 13 Jan 2010 Planned number of patients changed from 200 to 206 as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2009 Actual initiation date changed from May 2008 to Jul 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top